OSCIENT PHARMACEUTICALS COMPLETES SALES FORCE EXPANSION

Oscient Pharmaceuticals (Nasdaq: OSCI) has expanded the number of primary care pharmaceutical sales representatives detailing its products to 300. The national sales force is focused on promoting Oscient's fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets and Auxilium Pharmaceuticals' TESTIM(R) 1% testosterone gel. The 50 newest representatives, hired by Innovex, the contract sales arm of Quintiles Transnational Corp., have recently completed training and are now fully deployed in high potential territories.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1069771XSL_NEWSML_TO_NEWSML_WEB.xml)